GS-US-200-5717: A Phase 1 Study in Healthy Participants to Evaluate the Safety,Tolerability, and Pharmacokinetics of Subcutaneous andIntramuscular Lenacapavir
- Conditions
- HIVInfection - Acquired immune deficiency syndrome (AIDS / HIV)
- Registration Number
- ACTRN12623000535673
- Lead Sponsor
- Gilead Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 50
Have the ability to understand and sign a written informed consent form, Be aged 18 through 55 years, be a nonsmoker. The use of nicotine containing products must be discontinued 42 days prior to the administration of the study drug. Have a calculated body mass index not greater than 35.0 kg/m2 at screening, have a creatinine clearance (CLcr) at least 90 mL/min (using the Cockcroft-Gault method{Cockcroft 1976}), Participants who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception, Participants have not donated blood within 56 days of study entry or plasma within 7 days of study entry. Must be willing and able to comply with all study requirements.
Positive serum or urine pregnancy test, Breastfeeding female, Is currently participating in or has participated in an interventional clinical study with an investigational medicinal product within 30 days prior to study dosing on Day 1 through the duration of the study. Have current alcohol or substance abuse judged by the investigator, Assessed by the investigator as being at risk for HIV infection in the past 6 months, Have a positive test result for HIV at screening, Have a positive test result for hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening. Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study, Have a history of Significant serious skin disease, Significant drug sensitivity or drug allergy, Known hypersensitivity to the study drug, Significant cardiac disease, Syncope, palpitations, or unexplained dizziness, Implanted defibrillator or pacemaker, Liver disease, including Gilbert syndrome, Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions, Have any serious or active medical or psychiatric illness (including depression).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety and tolerability assessed by physical exam, injection site examinations, patient report pain questionnaire, review of concomitant medications, vitals signs, clinical laboratories (hematology, chemistry, creatinine clearance calculation, and urinalysis), serum pregnancy tests, 12-lead ECG, Adverse events and laboratory toxicities will be assessed and managed according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AEs, Version 2.1 dated July 2017. [ These will be assessed daily through confinement (Day -1 through Discharge Day 15 post-intervention administration) and then Days 22, 29, 36, 43, 57, 71, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 351, 365, 379 , 421, and 449 post-intervention administration. Telephone contacts will be conducted to review adverse events, and concomitant medications on Days 99, 127, 155, 183, 211, 239, 267, 295, 323, 407, and 435 post-intervention administration]
- Secondary Outcome Measures
Name Time Method Secondary Outcome: The following plasma PK parameters for LEN (and metabolites, if appropriate) will be calculated for each analyte, as applicable: AUCinf, AUClast, %AUCexp, Cmax, Tmax, Clast, Tlast, lambda z, CL/F, t1/2, and Vz/F[ Day 1 : 0 ( Pre dose less than/equal to 5 minutes before dose) 2,4,8, and 12 hours post dose.<br>Day 2 : 24 and 36 hours post dose.<br>A single anytime PK sample will be collected on Days 3,4,6,8,10,15,22,29,36,43,57,71,85,113,141,169,197,225,253,281,309,337,351,365,379,393,421,449 post-dose.<br>.]